Title: | The future of genetic diagnostisc tests |
Authors: | Karagenc, N. |
Keywords: | материалы конференций;diagnostisc tests;molecular genetic;information technologies |
Issue Date: | 2018 |
Publisher: | БГУИР |
Citation: | Karagenc, N. The future of genetic diagnostisc tests / N. Karagenc // BIG DATA Advanced Analytics: collection of materials of the fourth international scientific and practical conference, Minsk, Belarus, May 3 – 4, 2018 / editorial board: М. Batura [etc.]. – Minsk, BSUIR, 2018. – Р. 100. |
Abstract: | Molecular genetic tests become increasingly sophisticated. Until recently, genetic
tests were carried out on one or a few loci. The advent of large-insert clone arrays and, later, next
generation sequencing method changed this by allowing a patient’s entire genome to be searched at
improved resolution, thereby allowing the detection of medium to large genomic areas.
Detecting large genome areas and many mutations by genetic test allows us to detect numerous
mutations related by particular disease or particular condition. Development of detection methods of
genes have brought many new aspects in gene related health conditions and also the treatment of
certain diseases in this new era of clinical diagnostics tests.
Detecting large genom areas produces huge data to be analyzed which also leads the develop-
ment of genome screening-analizing softwares. Having this big data and developed softwares also
open a demand for work force in Information Technologies to do bioinformatic analysis. Therefore,
a new area has been developed combining clinical medicine and in research and medicine.
Data privacy will be another key component of the future of genetic tests. We must address
concerns about the privacy of patient data to take full advantage of large-scale analysis of aggregated
patient datasets, and to allow the healthcare industry to fully realize the economic benefits of cloud
computing. Protecting personel data also requires also legal legislations.
Whole genom analysis or detecting certain mutations also leads the pharmacetical companies
to discover new mutation specific drugs and alsopatient or individual lead gene terapy.
This work is supprted by the Project PauBap, Project number: 2018KRM002-550 |
URI: | https://libeldoc.bsuir.by/handle/123456789/31358 |
Appears in Collections: | BIG DATA and Advanced Analytics. Использование BIG DATA для оптимизации бизнеса и информационных технологий (2018)
|